

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**UNITED STATES DEPARTMENT OF COMMERCE****United States Patent and Trad mark Office**Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/674,800 11/06/00 STRUNGmann

T 4271-29PUS

EXAMINER

HM12/1017

THOMAS C PONTANI  
COHEN PONTANI LIEBERMAN & PAVANE  
SUITE 1210  
551 FIFTH AVENUE  
NEW YORK NY 10176

TRAN.S

ART UNIT	PAPER NUMBER
----------	--------------

1615

DATE MAILED:

10/17/01 4

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks**

<b>Office Action Summary</b>	Application No. <b>09/674,800</b>	Applicant(s) <b>Strungmann</b>
	Examiner <b>Susan Tran</b>	Art Unit <b>1615</b>

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1)  Responsive to communication(s) filed on \_\_\_\_\_.

2a)  This action is FINAL.      2b)  This action is non-final.

3)  Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

#### Disposition of Claims

4)  Claim(s) 16-31 is/are pending in the application.

4a) Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5)  Claim(s) \_\_\_\_\_ is/are allowed.

6)  Claim(s) 16-31 is/are rejected.

7)  Claim(s) \_\_\_\_\_ is/are objected to.

8)  Claims \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9)  The specification is objected to by the Examiner.

10)  The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

11)  The proposed drawing correction filed on \_\_\_\_\_ is: a)  approved b)  disapproved.

12)  The oath or declaration is objected to by the Examiner.

#### Priority under 35 U.S.C. § 119

13)  Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

a)  All b)  Some\* c)  None of:

1.  Certified copies of the priority documents have been received.

2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.

3.  Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\*See the attached detailed Office action for a list of the certified copies not received.

14)  Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

#### Attachment(s)

15)  Notice of References Cited (PTO-892)

18)  Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_

16)  Notice of Draftsperson's Patent Drawing Review (PTO-948)

19)  Notice of Informal Patent Application (PTO-152)

17)  Information Disclosure Statement(s) (PTO-1449) Paper No(s). 4

20)  Other:

Art Unit: 1615

## **DETAILED ACTION**

Receipt is acknowledged of applicant's Preliminary Amendment A filed 11/05/01, and Information Disclosure Statement filed 07/30/01.

### ***Specification***

1. This application does not contain an abstract of the disclosure as required by 37 CFR 1.72(b). An abstract on a separate sheet is required.

### ***Claim Rejections - 35 U.S.C. § 112***

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 16-31 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 16 and 28 are indefinite in the use of the phrase "selected from". If Markush language is intended, the appropriate phrasing is "selected from the group consisting of". Correction is suggested.

Art Unit: 1615

Regarding claim 27, the phrase "rubber-like" renders the claim(s) indefinite because the claim(s) include(s) elements not actually disclosed (those encompassed by "rubber-like"), thereby rendering the scope of the claim(s) unascertainable. See MPEP § 2173.05(d).

Claim 31 is indefinite in the use of the phrase "elected from the group consisting of". If Markush language is intended, the appropriate phrasing is "selected from the group consisting of". Correction is suggested.

***Claim Rejections - 35 U.S.C. § 102***

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371© of this title before the invention thereof by the applicant for patent.

Claims 16, 17, and 20-22 are rejected under 35 U.S.C. 102(e) as being anticipated by Frangin et al. US 5,985,915.

Frangin teaches a patch for transdermal composition comprising active ingredients, excipient (column 6, lines 24-65), and at least one additional cardioactive agent selected from the group consisting of diuretic, and angiotensin II, e.g., candesartan (column 8, lines 43-67).

Art Unit: 1615

***Claim Rejections - 35 U.S.C. § 103***

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 16-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Frangin et al.

Frangin is relied upon for the reasons stated above. In the case that applicant's attorney can over come the above 102(e) rejection, the examiner relies on the 103(a) rejection. Regarding to claims 18-22, the reference differs from the claimed invention by not teaching the specific form of candesartan or its' salts. However, it would have been *prima facie* obvious for one of the ordinary skill in this art to, by routine experimentation determine a suitable form of candesartan suitable for transdermal patch.

The examiner notes that Frangin is silent as to the teaching of diuretic or calcium blocker as a second therapeutic agent. However, Frangin teaches the active ingredients selected from benzofuran can be formulated in combination with one or more pharmaceutically vehicles (see abstract). Thus, it would have been obvious for one of the ordinary skill in this art to select more than one cardioactive agent, e.g. diuretic and angiotensin inhibitor, to obtain a transdermal patch containing candesartan.

Art Unit: 1615

5. Claims 16, 17, and 19-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Poss US 5,616,591, in view of Frangin et al.

Poss teaches a composition for transdermal patch comprising an angiotensin inhibitor agent in combination with a diuretic agent as a second compound (columns 7, lines 40 through column 8, lines 1-29). Poss does not suggest the use of a specific compound of angiotensin inhibitor.

Frangin teaches a transdermal patch composition comprising angiotensin inhibitor agent, e.g., candesartan (column 8, lines 66-67). Thus, it would have been prima facie obvious for one of the ordinary skill in the art to modify Poss's transdermal patch using candesartan as an angiotensin agent in view of the teaching of Frangin. The reasons for this modification is to obtain a transdermal patch containing candesartan useful for the treatment of heart diseases.

6. Claims 23-31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Poss and Frangin et al., in view of Jalonen et al. US 5,464,628.

Poss and Frangin are relied upon for the reasons stated above. The references are silent as to the teaching of the ingredients of a transdermal patch.

Jalonen teaches a pharmaceutical composition containing substituted imidazoles to be administered transdermally (abstract). The transdermal patch comprises a an impermeable backing layer and an adhesive layer; or an impermeable backing layer, an adhesive layer, and a matrix layer; or a drug reservoir system (column 2, lines 36-64). The backing layer can be

Art Unit: 1615

flexible or non-flexible materials: polyethylene, or polypropylene; the adhesive layer can be polysiloxanes, polyacrylates, or ethylene-vinyl acetate; and the matrix layer can be of natural or synthetic rubbers (column 3, lines 21-51). The composition further comprising carrier and penetration enhancers, e.g., polyethylene glycol, propylene glycol, isopropanol, ethanol, oil, or a mixture thereof (column 2, lines 65 through column 3, lines 1-20). Thus, it would have been *prima facie* obvious for one of the ordinary skill in this art to prepare Poss's and Frangin's composition in a transdermal patch in view of the teaching of Jalonen. The reasons for this modification is to obtain a candesartan transdermal patch that will provide a high bioavailability of drug penetration.

***Pertinent Arts***

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Chen et al. is cited as being of interest for the teaching of candesartan in transdermal form.

***Correspondence***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Tran whose telephone number is (703) 306-5816. The examiner can normally be reached on Monday through Thursday from 6:00 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page, can be reached on (703) 308-2927. The fax phone number for the organization where this application or proceeding is assigned is (703) 305-3592.

Art Unit: 1615

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.



THURMAN K. PAGE  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600